Introduction
Dietary/food supplements, marketed as self-medication products, are promoted and perceived as safe by the public because of their natural components. This has resulted in increased consumption over the years, with more than half of US adults reporting use of supplements in 2011-2012, especially multivitamins [1] .
The European Directive 2002/46/EC defines food supplements as ''foodstuffs, the purpose of which is to supplement the normal diet and which consist of a concentrated source of nutrients or other substances with nutritional effects or physiological, single or in combination, marketed in dosed formulations, such as capsules, pastilles, tablets, pills, etc., designed to be taken in small individual quantities measured'' [2] . The regulatory status of ''nutraceuticals'' is a current challenge, and an officially accepted definition of these products is still lacking [3] . As compared to medicinal products, food supplements do not need to prove clinical efficacy in a specific health condition. Moreover, safety is currently uncertain; several case series have documented the occurrence of life-threatening adverse events (AEs) with the administration of these products [4] [5] [6] [7] [8] , and the latest US survey estimated that 23,000 visits per year to emergency departments are attributed to food supplements [9] .
Red yeast rice (RYR) is a paradigmatic example of the current regulatory debate: while the European Food Safety Authority granted the health claim in 2011 by establishing a cause-effect relationship between the consumption of at least 10 mg of monacolin K in RYR preparations and maintenance of normal cholesterol levels [10] , the Food and Drug Administration (FDA) maintains a different perspective. Because of its functional similarity to lovastatin, monacolin K is considered an unapproved drug, and as such, all RYR products that contain a specific amount of monacolin K are prohibited [11] . In fact, RYR supplements on the market are not standardized and contain variable amounts of monacolins [12, 13] , with the latest data estimating up to 120-fold variations in daily monacolin K intake based on 26 tested brands [14] .
Because of its documented lipid-lowering properties in humans [15, 16] , RYR is largely proposed as a safer alternative in statin-intolerant patients or even in naïve individuals with mild hypercholesterolemia who are skeptical of drugs. However, safety is still incompletely characterized; the majority of data stem from a systematic review (with different methodological issues of included studies [17] ), clinical trials (underpowered to identify safety signals and only rarely comparing head-to-head RYR with statins or ezetimibe), and isolated case reports/case series, which provided detailed causality assessment, but represent only a limited picture of the phenomenon. Previous studies highlighted myopathies and liver injuries as potential safety concerns [18] [19] [20] [21] [22] , thus raising the hypothesis that RYR's risk profile is similar to that of statins and calling for continuous monitoring to inform consumers about possible risks, promote proper use by clinicians, and support policymakers in regulatory measures [23] .
The aforementioned peculiarities of RYR, in turn, cause uncertainty in the process to properly notify safety issues occurring during its administration. In fact, reporting of AEs with dietary/food supplements is heterogeneous; they can be registered in pharmacovigilance databases of adverse drug reactions or can be submitted via dedicated (albeit less well known) spontaneous reporting systems.
The aim of this study was to describe and compare AEs associated with food supplements containing RYR submitted to spontaneous reporting systems maintained by the FDA and, more specifically, to verify whether previously raised signals of muscular/hepatic toxicity in France and Italy [21, 22] were confirmed in larger US databases.
Methods

Study Conception
Building on the notion that RYR contains pharmacologically active ingredients and is likely to be used by patients receiving polypharmacy, we exploited (1) [8] . Considering that FDA reports are sorted according to the product believed to be associated with the AE, and the fact FAERS and CAERS are independent archives currently not digitally linked, redundancy (i.e., the existence of overlapping reports across databases) is highly unlikely.
Data Sources
The [8] . Data files, consisting in different tables, can be accessed and freely downloaded to extract and analyze individual case reports in terms of demographic data (age and sex), suspected product's name, AE outcomes, and symptoms [24] . In CAERS, an automated de-duplication process was not applied, although the FDA removes duplicate reports when detected. The role of the individual product is generally indicated as ''suspect'' or ''concomitant.'' FAERS represents the largest publicly available database of adverse drug reactions, collecting US and non-US reports (for serious AEs) spontaneously submitted by drug companies, healthcare professionals, and consumers. Since 2004, raw data have been able to be accessed and downloaded [25] , although the different tables/files must be extensively pre-processed through multistep data-mining algorithms to select reports above a pre-specified level of quality. As detailed in a dedicated book chapter [26] , automated strategies were a priori systematically applied to detect and remove duplicates (i.e., reports with overlaps in three out of four key fields, namely event date, age, gender and reporter country) and to standardize drug names into active substances with relevant Anatomical Therapeutic Chemical codes. In FAERS, the reporter may specifically indicate the role of the drug in AE occurrence as ''primary suspect,'' ''secondary suspect,'' ''interacting'' or ''concomitant.''
Study Design
The study was conceived as a descriptive analysis (demographic information and relevant frequencies of AEs) followed by a disproportionality approach with case-by-case assessment, where applicable. As a first step, since a repository of available RYR products is not universally available to our knowledge, we checked the following publicly available databases of natural products to create a list of common RYR names: www.drugs.com, the Natural Medicines Comprehensive Database (http://naturaldata base.therapeuticresearch.com/nd/Search.aspx?s=ND&cs= &pt=1&spt=1&rli=1&anchor=basic#basic), and the Dietary Supplement Label Database from the National Center for Complementary and Integrative Health (https://dsld. nlm.nih.gov/dsld/). The following key words were used to extract RYR products in both databases: monacolin k, Monascus, Monascus purpureus, hongqu, red koji, zhitai, xuezhikang, rotschimmelreis, cholestin, and red yeast rice. In order to be comprehensive, all possible combinations of the string ''red yeast rice'' were exploited: *red yeast rice*, *red rice yeast*, *yeast red rice*, *yeast rice red *, *rice red yeast*, *rice yeast red*, *red rice*, *red yeast*, *rice yeast*, *yeast rice*, *rice red*, and *yeast red*.
AEs are coded by the FDA through the Medical Dictionary for Regulatory Activities (MedDRA Ò ) terminology in terms of preferred terms (PTs), which identified a given sign/ symptom. In FAERS, a given individual case safety report (ICSR) may contain multiple AEs (reported in the ''REAC'' field); the same applies to CAERS, where an ICSR may be linked to different AEs recorded in the ''SYM_One Row Coded Symptoms'' field. These PTs were assigned to the socalled system organ class (SOC) to classify the type and frequency of AEs, using MedDRA Ò version 19. A single report may count manyfold times depending on the number of AEs (assigned to a unique SOC).
A disproportionality analysis (known as a case/non-case study) focusing on muscular and hepatic events was performed. Cases were defined by reports containing liver/muscular AEs, whereas non-cases were all other reports (i.e., those without such AEs), i.e., an ICSR is counted only once [27] . To this aim, the reporting odds ratio (ROR) was calculated with its relevant 95% confidence interval (CI), with the threshold for significance defined by a lower limit of the 95% CI [ 1 with at least three cases of interest, now referred to as signal of disproportionate reporting (SDR). The ROR was calculated for RYR and, in FAERS, for statins, which were tested as a positive control to evaluate the accuracy of the approach in highlighting true positives. As a sensitivity analysis, we planned to compare the reporting of RYR with AEs submitted for statins, in order to have a broad suggestion of the head-to-head relative reporting. Despite limitations, the ROR is a standardized disproportionality approach in pharmacovigilance assessment, and may provide an initial indication of the likely clinical importance of an AE (i.e., strength of the association), especially for events with a recognized drug-related component such as rhabdomyolysis [28] . The ROR method was calculated for two SOCs of interest (''hepatobiliary disorders'' and ''musculoskeletal and connective tissue disorders'') and relevant serious events comprising a specific syndrome [known as a standardized MedDRA query (SMQ)]: ''drug-related hepatic disorderssevere events only'' and ''rhabdomyolysis/myopathy''. For this purpose, PostgreSQL software version 9.5 was used.
Finally, a case-by-case analysis was carried out on serious muscular and liver AEs where RYR products were reported as suspect, to assess plausibility and potential causality (e.g., onset and co-medications).
Results
In FAERS, 1300 ICSRs were extracted (0.02% of total reports), corresponding to 3541 AEs, which mainly occurred in females (66%) and were submitted by US consumers (88%). RYR was mainly reported as ''concomitant'' (85%), although serious outcomes occurred (death or hospitalization in 16%). In CAERS, 159 ICSRs were included (0.3% of total reports), corresponding to 446 AEs, with a higher female percentage (67%); in 105 reports, RYR was considered suspect (Table 1) .
''General disorders and administration site conditions'' were the most frequently reported SOCs in both FAERS and CAERS (16%); ''musculoskeletal and connective tissue disorders'' represented 7.5 and 11.7% of total AEs (FAERS and CAERS, respectively), whereas ''hepatobiliary disorders'' were * 1% (Fig. 1) . Statistically significant disproportionalities emerged for the majority of SOCs in FAERS, including ''general disorders and administration site conditions'' (N = 548; ROR = 2.6; 95% CI = 2.3-2.9), ''gastrointestinal disorders'' (344; 3.3; 2.9-3.7), and ''nervous system'' (337; 2.9; 2.6-3.3). In CAERS, five SOCs generated SDRs, including ''general disorders and administration site conditions'' (N = 71; ROR = 2.1; 95% CI = 1.5-2.9), ''investigations'' (64; 3.6; 2.6-4.9), and ''musculoskeletal and connective tissue disorders'' (52; 8.5; 6.1-11.9) (see Electronic Supplementary Material 1).
With regard to the two SOCs of interest, SDRs emerged for RYR and statins (positive control). The analysis on serious events at the SMQ level generated seven SDRs: in FAERS, five cases of hepatic events were detected for RYR (ROR = 13.71; 95% CI = 5.44-34.57) and 21 were retained for muscular SMQ (20.37; 11.6-35.9); in CAERS, one case of liver damage and 27 cases of rhabdomyolysis/ myopathy were recorded (8.44; 5.44-13.10). Sensitivity analysis comparing RYR with statins maintained statistical significance at the SMQ level (Table 2) .
Case-by-case analysis highlighted that (1) in FAERS (24 patients, corresponding to 26 AEs), four cases were plausible (no concomitant drugs were reported; onset 33-147 days), 11 cases were not fully assessable due to missing data (in nine, previous statins/lipid-lowering drugs were recorded), and nine were uncertain (the onset was before RYR use; all with previous lipid-lowering agents) (for details, see Electronic Supplementary Material 2); and (2) in CAERS (27 patients), concomitant agents were recorded only in eight cases (no statins, mainly multivitamins).
Discussion
Although RYR-containing products have been on the market for several years, their safety profile mainly relies on case reports/series [18] [19] [20] [21] [22] . Considering that a recent systematic review concluded that the safety of RYR is uncertain due to methodological issues of included clinical trials, spontaneous reports represent the most valuable source for safety assessment, although food supplements may escape detection from common pharmacovigilance databases of adverse drug reactions because of their regulatory status (they are not considered medicinal products notwithstanding their pharmacological properties). The aim of this post-marketing analysis was to describe and compare AEs associated with RYR products in publicly accessible US spontaneous reporting systems and, more specifically, to confirm the existence of clinically relevant muscular/hepatic toxicities. From a methodological standpoint, for the first time, we provided the largest analysis of reported AEs by documenting the possibility of combining FAERS, a drug-based database, and CAERS, a recently release repository of AEs specifically implemented to monitor the safety of cosmetics and food supplements. This approach, only rarely performed in post-marketing safety assessment of medicines, underlines the importance of exploring different databases to fully capture reporting patterns of RYR products. The current scenario of reporting for food supplements and other healthcare substances is heterogeneous: while Italy and the USA have set up a dedicated repository, different countries such as Canada and the UK comprehensively collect AEs with drugs, devices and health products. This increases the complexity of food supplement safety analysis design.
From a clinical standpoint, our data are in line with recent European case series [21, 22] , with gastrointestinal, nervous system, musculoskeletal/connective tissue and skin/subcutaneous disorders as the most frequently reported AEs. From an epidemiological viewpoint, the number of AEs submitted to US databases is noteworthy in FAERS and largely outweighed even those recorded from the World Health Organization's VigiBase (1300 vs 75), although differences in data access and level of analyses do not allow direct comparison [22] . Disproportionality and case-by-case analyses confirmed that serious muscular and hepatic toxicities do occur with food supplements containing RYR. These signals were consistently detected in both databases and, intriguingly, the sensitivity analysis showed that the reporting frequencies of muscular and hepatic injuries are even higher when compared to statins, although this type of analysis cannot be used as a standalone approach to directly compare RYR with statins in terms of safety. Although incomplete information does not allow conclusive assessment, the individual inspection of cases revealed a statin-use history in the majority of patients; these findings, together with the reporter's suspicion, raise the hypothesis that these events might continue with RYR. Considering that expected under-reporting is likely to affect the so-called ''natural'' products to a larger extent (as compared to drugs) [29, 30] and no stimulated reporting should have occurred (no warnings/media attention were previously posted for RYR, differently from statins), our data strengthen the notion that the risk profile of foo supplements containing RYR is driven by intrinsic pharmacological properties and support the evidence that RYR is not a safe alternative to statins [31] .
Vigilance at all levels of the healthcare systems should be strengthened, including monitoring of spontaneous reporting systems worldwide. Consumers should be informed about content/composition, product strength and possible AEs, to avoid duplicate therapy or tentative switching. Clinicians should consider (1) the pharmacological lipid-lowering property of RYR and avoid the prescribing cascade of co-administration with statins [32] and (2) the additional inhibitory effects on different isoforms of cytochrome P450 (1A2, 2C19, 3A4) and the increased activity on glycoprotein P, which may result in drug-drug interactions with increased risk of AEs [33] . Therefore, recommendations for hepatic and muscular monitoring during treatment (clinical and laboratory) should be extended to RYR products. A recent case report described a 39-year-old male patient who developed erectile dysfunction after 1 week of RYR intake for self-therapy, with positive dechallenge after 3 weeks. Intriguingly, a slight increase in progesterone level emerged and unspecific effects on blood lipids were found (with thrombogenic apo a remarkably raised) [34] . These findings raise interest and uncertainty regarding the precise mechanism of action of RYR and call for active monitoring of potential off-target AEs in clinical practice.
We acknowledge the limitations of this study, which does not allow assessment of actual risk in clinical practice and calculation of incidence rates, because of the lack of In FAERS, total reports (denominator) were 7,346,371 when RYR was compared to all other drugs, and it was 522,428 when RYR was compared to statins. In CAERS, the denominator was 55,341 (see Table 1) b
Cases are the number of reports with the event of interest attributed to RYR or statins, whereas non-cases are the number of reports where the event of interest was attributed to other drugs/products certainty in AE occurrence and the unknown number of exposed patients, respectively. Moreover, missing data on temporal plausibility (mainly in CAERS) and difficulties in retracing the precise sequence of therapy from medical histories (FAERS) do not allow definite case-by-case evaluation of all serious reports. Finally, composition of the different products was not available, thus adding further complexities in making a causality assessment.
There is a common and urgent need to harmonize the regulatory status of RYR [35] . A recent ''benchmark dose'' approach identified 6 mg/day of lovastatin as a threshold for pharmacological action [36] . Accordingly, in 2016, the Joint Commission of Experts of the Federal Office of Consumer Protection and Food Safety and the Federal Institute for Drugs and Medical Devices in Germany decided that products with a dose of monacolin K higher than 5 mg/day should be classified as drugs [37] .
Conclusions
FAERS and CAERS provide complementary information on the safety profile of RYR, with similarities and differences in terms of reporting pattern. Overall, half of reports were submitted by consumers, mainly females, and approximately 15% of patients were hospitalized. In FAERS, RYR was mainly reported as ''concomitant,'' whereas in CAERS, it was reported as ''suspect'' regarding the AEs. Signals of serious hepatic and muscular toxicities emerged in both databases and underline the importance of using multiple data sources in safety assessment of RYR products. Real-world vigilance should be strengthened at different levels, including consumers, clinicians and policymakers to promote proper use and harmonize the regulatory status of RYR.
